Research location
Ocala
Florida, United States
Research activity in Ocala
Florida, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 559 trials and 601 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ocala
559 linked trials · page 2 of 12BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)NCT06773910 · 2025-03-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · 2025-03-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · 2025-01-29 · 2 site observations
COMPLETED
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)NCT06750432 · 2024-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With ObesityNCT06717425 · 2024-12-09 · 2 site observations
COMPLETED
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · 2024-11-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153 · 2024-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseNCT06602258 · 2024-09-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · 2024-09-30 · 1 site observation
COMPLETED
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor ComplicationsNCT06553027 · 2024-09-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseNCT06538116 · 2024-08-26 · 1 site observation
COMPLETED
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · 2024-06-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093 · 2024-04-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 · 2024-04-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207 · 2024-04-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseNCT06268886 · 2024-03-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306 · 2024-01-11 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseaseNCT06055985 · 2023-11-17 · 1 site observation
COMPLETED
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult ParticipantsNCT05963984 · 2023-11-16 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisNCT06025578 · 2023-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086 · 2023-09-22 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · 2023-07-11 · 1 site observation
COMPLETED
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsNCT05671510 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
Phase III Study of AK112 for NSCLC PatientsNCT06396065 · 2023-05-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaNCT05692180 · 2023-04-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation
COMPLETED
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADNCT05686044 · 2023-04-01 · 1 site observation
COMPLETED
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDNCT05819359 · 2023-03-31 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)NCT05813288 · 2023-03-27 · 1 site observation
TERMINATED
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's DiseaseNCT05766813 · 2023-03-13 · 1 site observation
COMPLETED
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerNCT05654623 · 2023-03-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486 · 2023-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · 2023-02-01 · 1 site observation
COMPLETED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaNCT05748600 · 2023-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsNCT05653882 · 2023-01-04 · 1 site observation
ACTIVE_NOT_RECRUITING
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCNCT05468489 · 2022-11-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Open-label Extension for Phase 3 Clinical Trials of SimufilamNCT05575076 · 2022-11-07 · 1 site observation
TERMINATED
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)NCT05514535 · 2022-08-29 · 1 site observation
COMPLETED
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's DiseaseNCT05291234 · 2022-08-15 · 1 site observation
COMPLETED
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDNCT05357989 · 2022-08-03 · 1 site observation
COMPLETED
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)NCT05463731 · 2022-08-01 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerNCT05275673 · 2022-07-21 · 1 site observation
TERMINATED
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsNCT05397600 · 2022-06-22 · 1 site observation
COMPLETED
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaNCT05412004 · 2022-06-21 · 1 site observation
COMPLETED
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)NCT05364307 · 2022-06-13 · 1 site observation
COMPLETED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.